Search
LY-517717
go.drugbank.com/drugs/DB05713InvestigationalLY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
ORG-34517
go.drugbank.com/drugs/DB05423InvestigationalIt has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Cardarine
go.drugbank.com/drugs/DB05416InvestigationalCardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.
EHC18
go.drugbank.com/drugs/DB05114ExperimentalEHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.
DNB-001
go.drugbank.com/drugs/DB05757InvestigationalIn preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve. … DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.
CY301
go.drugbank.com/drugs/DB06382ExperimentalCY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.
AT-301
go.drugbank.com/drugs/DB16507InvestigationalAT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine
NXN-188
go.drugbank.com/drugs/DB06096InvestigationalNXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Veru-111
go.drugbank.com/drugs/DB16462Investigationalin adults, and metastatic triple-negative breast cancer. … VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.
8-chlorotheophylline
go.drugbank.com/drugs/DB14132ExperimentalBecause adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation. … Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate].